Spinifex appoints Declan Doogan non-executive chair
This article was originally published in Scrip
Spinifex Pharmaceuticals, an Australian pain drug development company, has appointed Dr Declan Doogan, who has 30 years' experience of the pharmaceuticals industry, non-executive chair. Dr Doogan is currently chief medical officer of Amarin Corporation and served as interim CEO of the company from 2009-10. Prior to joining Amarin in 2007, Dr Doogan spent 20 years at Pfizer, most recently as senior vice-president and head of worldwide development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.